Reta GLP-3R 20mg Vial

What is RETA GLP-3?

“RETA GLP-3” is a nickname used online for retatrutide (also known as LY3437943), an investigational synthetic peptide designed to activate three hormone receptors involved in metabolic regulation: GLP-1, GIP, and the glucagon receptor. Reuters+1

Retatrutide is not approved for general medical use and is being evaluated in late-stage clinical trials for obesity and related metabolic conditions. Reuters+2ClinicalTrials+2

Why it is being studied

Researchers are studying triple-agonist therapies like retatrutide to better understand and potentially influence:

• appetite and satiety signaling

• glucose regulation and insulin dynamics

• energy expenditure and lipid handling Reuters

How it works (mechanism overview)

Retatrutide is designed to engage three pathways at once:

1) GLP-1 receptor activity

• supports glucose-dependent insulin secretion

• contributes to satiety signaling and reduced food intake

• slows gastric emptying (which can affect post-meal glucose dynamics) Reuters

2) GIP receptor activity

• can further augment glucose-dependent insulin response

• is being explored for its role in metabolic regulation when combined with other incretin pathways Reuters

3) Glucagon receptor activity

• is studied for its potential role in energy expenditure and lipid metabolism when paired with incretin activity Reuters

What clinical research has reported so far (high level)

Across clinical research programs, retatrutide has been reported to produce meaningful changes in body weight and cardiometabolic markers, though outcomes vary by population, dose, and study design. Reuters+1

In a randomized phase 2a trial in people with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide was associated with large reductions in liver fat compared with placebo, alongside reductions in body weight and waist circumference in that study population. Nature

Chemical identifiers (public registries)

• Generic name: retatrutide

• Synonym / code: LY3437943

• CAS: 2381089-83-2

• UNII: NOP2Y096GV

• Molecular formula: C221H342N46O68

• Molecular weight: ~4,731 Da precision.fda.gov

Important note

Because retatrutide is investigational, it should be handled and discussed in the context of legitimate research and regulated clinical development, not as an approved consumer product. The Verge+1

Sources (different from the ones you used)

• ClinicalTrials.gov study records for retatrutide in obesity/overweight and type 2 diabetes ClinicalTrials+1

• Nature Medicine phase 2a MASLD trial Nature

• FDA GInAS substance record (UNII NOP2Y096GV) precision.fda.gov

• Reuters reporting on late-stage trial results and program status Reuters

• 2025 review discussing triple-agonism therapies Springer Link